<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107637</url>
  </required_header>
  <id_info>
    <org_study_id>NBS_2016_12</org_study_id>
    <nct_id>NCT03107637</nct_id>
  </id_info>
  <brief_title>Transesophageal Echocardiography in Embolic Stroke of Undetermined Source</brief_title>
  <acronym>ETO</acronym>
  <official_title>Therapeutic Implications of Early Transesophageal Echocardiography in Embolic Stroke of Undetermined Source (ESUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      The ESUS concept was introduced recently to describe a non-lacunar stroke of undetermined&#xD;
      etiology. The following etiological workup is required in this setting: head CT or MRI,&#xD;
      12-lead ECG, transthoracic echocardiography, continuous cardiac monitoring for at least 24&#xD;
      hours after stroke, vascular imaging (ultrasound, magnetic resonance angiography, CT&#xD;
      angiography, catheter angiography). Transesophageal echocardiography (TEE) is considered not&#xD;
      to be required.&#xD;
&#xD;
      However, aortic arch atheroma as diagnosed by TEE in the setting of recent ischemic stroke is&#xD;
      a major aortic source of embolism, as supported by numerous well conducted studies. The&#xD;
      European Association of Echocardiography considers that TEE is the gold standard for the&#xD;
      diagnosis and the characterization of aortic atheroma. It is also the method of choice for&#xD;
      the diagnosis of infectious endocarditis.&#xD;
&#xD;
      The aim of this work was to evaluate the rate of patients with a therapeutic modification&#xD;
      induced by TEE (mainly anticoagulation and surgery), in consecutive patients admitted with&#xD;
      ESUS at our institution stroke unit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 3, 2016</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>therapeutic modification after transesophageal echocardiography</measure>
    <time_frame>24 hours after TEE</time_frame>
    <description>proportion of patients with a therapeutic modification (mainly anticoagulation and surgery)</description>
  </primary_outcome>
  <enrollment type="Actual">186</enrollment>
  <condition>Embolic Stroke of Undetermined Source</condition>
  <condition>Ischemic Stroke</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients followed for ichemic stroke meeting embolic source of unknown source criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presenting with a new onset of ischemic stroke&#xD;
&#xD;
          -  Meeting the ESUS criteria (Embolic Stroke of Undetermined Source)&#xD;
&#xD;
          -  Comprehensive transthoracic echo prior to the TEE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ESUS criteria not met&#xD;
&#xD;
          -  Contraindications to TEE&#xD;
&#xD;
          -  TEE failure&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Person under legal protection&#xD;
&#xD;
          -  No medical insurance coverage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia Benyounes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique A. de Rothschild</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>June 20, 2021</last_update_submitted>
  <last_update_submitted_qc>June 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Embolic Stroke of Undetermined Source</keyword>
  <keyword>transesophageal echocardiography</keyword>
  <keyword>cardiac source of embolism</keyword>
  <keyword>ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Embolic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

